ClinicalTrials.gg
RecruitingNCT07328698OZONE-HERNIAUpdated Feb 11, 2026

Postoperative Ozonated Oil Dressing After Open Inguinal Hernia Repair: A Randomized Pilot Trial

An interventional study of ozonated oil and Standard Sterile Dressing in Inguinal Hernia Unilateral and Postoperative Wound Inflammation, sponsored by Nigde Omer Halisdemir University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Nigde Omer Halisdemir University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Hernia, Inguinal with a site in Turkey — 12 open to participants now, 14 under way, none of them phase 3. Hernia, Inguinal · Turkey.

Planned enrollment
38th of 60
60 · median 80
Started
2026
with 8 others
No phase
52 of 77
11 open now
Primary completion
2026-04
later than 2 of 13 live
Registered
65th of 77
by date
Lead sponsor
3 of 77
Nigde Omer Halisdemir University

Among the 77 studies in Hernia, Inguinal with a site in Turkey, this one is the 38th largest by planned enrollment of the 60 interventional ones that give a count, is one of 9 that started in 2026, is one of 52 with no phase, reaches primary completion later than 2 of the 13 other live ones, and was the 65th registered.

Hernia, Inguinal

545 studies on the registry are indexed under Hernia, Inguinal; 91 are open to participants now.

Browse Hernia, Inguinal studies →

Open to participants now

12 of the 77 studies in Hernia, Inguinal with a site in Turkey are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 54 Hernia, Inguinal studies recruiting now, 30 (56%) set no upper age limit and 16 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Hernia, Inguinal with a site in Turkey, or all of them as a file.
02

Study summary

This study looks at whether a special wound dressing containing ozonated oil can reduce early wound inflammation after open inguinal hernia surgery. Open inguinal hernia repair is a common operation, and although infection rates are low, many patients experience redness, swelling, tenderness, or discomfort at the surgical site during the first days after surgery.

Participants undergoing elective open inguinal hernia repair will be randomly assigned to receive either an ozonated oil-impregnated dressing or a standard sterile dressing after the operation. The main outcome is the level of wound inflammation measured on the third day after surgery. Other outcomes include wound temperature, pain levels, cosmetic healing, and wound-related problems during the first 30 days.

The ozonated oil used in this study is a CE-certified medical product that is already used in routine wound care. This pilot study aims to provide preliminary data to help determine whether ozonated oil dressing may improve early wound healing compared with standard care.

Read the detailed description

Early postoperative wound inflammation following open inguinal hernia repair may affect patient comfort, recovery experience, and cosmetic outcome, even in the absence of surgical site infection. Although open mesh inguinal hernia repair is classified as clean surgery, localized inflammatory findings such as erythema, edema, tenderness, and increased wound temperature are commonly observed during the early postoperative period.

Ozonated oil is a CE-certified topical medical product that has been used in routine clinical practice for wound care in dermatology, plastic surgery, and chronic wound management. Its proposed mechanisms include antimicrobial activity, modulation of local inflammatory response, and support of tissue repair. However, randomized evidence evaluating its effect on early inflammatory response in clean elective surgical incisions remains limited, and most existing studies rely primarily on subjective assessments.

This single-center, prospective, randomized pilot controlled trial is designed to compare ozonated oil-impregnated dressing with standard sterile dressing after elective open inguinal hernia repair. The study focuses on early wound inflammation rather than infection as the primary endpoint, using a composite clinical and photographic inflammation score assessed by blinded evaluators. Objective assessment of local inflammation is supported by non-contact infrared wound surface temperature measurement.

Due to the low expected incidence of surgical site infection in this surgical setting, the study is not powered to detect statistically significant differences in infection rates. Infection-related outcomes are therefore collected for exploratory purposes only. As a pilot trial, the primary aim is to generate preliminary data on feasibility, effect size, and outcome variability to inform the design of future larger-scale randomized studies.

03

Conditions studied

  • Inguinal Hernia Unilateral
  • Postoperative Wound Inflammation

Browse trials for

Keywords

  • Inguinal hernia repair
  • Open inguinal hernia surgery
  • Ozonated oil
  • Ozonated oil dressing
  • Postoperative wound inflammation
  • Surgical wound care
  • Topical ozone
  • Pilot randomized controlled trial
  • Clean surgical wound
  • Wound surface temperature
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 75 years
  • I-III
  • Scheduled for elective, unilateral open inguinal hernia repair
  • Able to provide written

Exclusion criteria

Exclusion Criteria:

  • Emergency inguinal hernia (incarcerated or strangulated)
  • Recurrent inguinal hernia
  • Concomitant surgical procedures during the same operation
  • or long-term systemic use
  • Use of anticoagulant or antiplatelet therapy
  • Known bleeding disorders
  • Active dermatologic disease at the surgical incision site
  • Pregnancy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Ozonated Oil Dressing

    Participants receive a sterile gauze dressing impregnated with CE-certified ozonated oil applied to the surgical incision after skin closure. The dressing is changed once daily for the first 48 hours, followed by standard wound care.

    Drug: ozonated oil

  • Active comparator
    Standard Sterile Dressing

    Participants receive a standard sterile dry dressing applied to the surgical incision after skin closure. The dressing is removed within 24-48 hours postoperatively, and subsequent wound care is continued according to routine institutional practice.

    Other: Standard Sterile Dressing

Interventions

  • Drugozonated oil

    Ozonated oil-impregnated sterile gauze is applied topically to the surgical incision immediately after skin closure. The dressing is changed once daily for the first 48 hours postoperatively, followed by standard wound care according to institutional routine.

  • OtherStandard Sterile Dressing

    A standard sterile dry dressing is applied to the surgical incision after skin closure and removed within 24-48 hours postoperatively. Subsequent wound care is continued according to routine institutional practice.

06

What researchers measure

Primary outcomes

  1. Composite Wound Inflammation Score

    A composite wound inflammation score ranging from 0 to 12, consisting of erythema, edema, and exudate graded from standardized wound photographs (0-3 points each) and wound tenderness assessed during clinical examination (0-3 points). Wound photographs are independently evaluated by two blinded surgeons.

    Time frame: Postoperative day 3

Secondary outcomes

  1. Wound Surface Temperature Difference

    Difference between mean surgical wound surface temperature and contralateral symmetrical skin temperature measured using a non-contact infrared thermometer.

    Time frame: Postoperative day 3

  2. Postoperative Pain Score

    Pain intensity at the surgical site measured using a 0-10 visual analog scale (VAS).

    Time frame: 6 hours, 24 hours, and postoperative day 3

  3. Cosmetic Outcome Score

    Patient-reported cosmetic satisfaction assessed using a 0-10 visual analog scale and photographic evaluation using the Hollander Wound Evaluation Score.

    Time frame: Postoperative day 30

  4. Surgical Site Infection

    Incidence of surgical site infection defined according to Centers for Disease Control and Prevention (CDC) criteria, collected for exploratory analysis.

    Time frame: Within 30 postoperative days

  5. Additional Antibiotic Use or Unplanned Healthcare Visits

    Any wound-related antibiotic treatment or unplanned medical visits due to wound complications during the postoperative follow-up period.

    Time frame: Within 30 postoperative days

07

Study locations

1 of 1 sites recruiting
  • Dr. Ali Rıza Erdoğan Private Practice Office
    Niğde, Niğde Province, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because this is a single-center pilot study with a small sample size, and the dataset includes clinical and photographic wound data that could pose a risk of re-identification. Data sharing was not planned at the time of study design.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Apr 2026, 2 months after the start.

Of 179 non-industry interventional studies with no phase under Hernia, Inguinal, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 2 months is below that.

Counting every sponsor, half of 188 studies reached it within 19 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2025
First posted
Jan 9, 2026
StartActual
Feb 10, 2026
Primary completionEst.
Apr 30, 2026
CompletionEst.
May 31, 2026
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07328698
Lead sponsor
Nigde Omer Halisdemir University
Responsible party
Alirıza Erdoğan (Medical doctor, General surgery, Nigde Omer Halisdemir University) — Principal investigator
First posted
Jan 9, 2026
Start date
Feb 10, 2026
Primary completion
Apr 30, 2026 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Feb 11, 2026

Study contacts

Ali Rıza Erdoğan, Medical doctor
Contact
dralirizaerdogan@gmail.com
+905333558377
Ali Rıza Erdoğan, Medical doctor
principal investigator · Private practice office

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion